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Improved tuberculosis diagnostics and tools for monitoring treatment response are urgently needed. 
We developed a robust and simple, PCR-based host-blood transcriptomic signature, RISK6, for multiple 
applications: identifying individuals at risk of incident disease, as a screening test for subclinical 
or clinical tuberculosis, and for monitoring tuberculosis treatment. RISK6 utility was validated by 
blind prediction using quantitative real-time (qRT) PCR in seven independent cohorts. Prognostic 
performance significantly exceeded that of previous signatures discovered in the same cohort. 
Performance for diagnosing subclinical and clinical disease in HIV-uninfected and HIV-infected persons, 
assessed by area under the receiver-operating characteristic curve, exceeded 85%. As a screening test 
for tuberculosis, the sensitivity at 90% specificity met or approached the benchmarks set out in World 
Health Organization target product profiles for non-sputum-based tests. RISK6 scores correlated with 
lung immunopathology activity, measured by positron emission tomography, and tracked treatment 
response, demonstrating utility as treatment response biomarker, while predicting treatment failure 
prior to treatment initiation. Performance of the test in capillary blood samples collected by finger-prick 
was noninferior to venous blood collected in PAXgene tubes. These results support incorporation of 
RISK6 into rapid, capillary blood-based point-of-care PCR devices for prospective assessment in field 
studies.
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Figure 1. Discovery of the RISK6 signature. (a) Expression kinetics of the six transcripts in RISK6 signature 
over time, measured by RNA-sequencing and expressed as log2 fold change between matched adolescent 
progressors and controls and modelled as non-linear splines (dotted lines). Light green shading represents 95% 
CI for the temporal trends, computed by performing 2000 spline fitting iterations after bootstrap resampling 
from the full dataset. Transcripts that are upregulated during TB progression are on the left and those that 
are downregulated on the right. (b) RISK6 comprises nine pairs that each link a transcript that is upregulated 
during TB progression with one that is downregulated, relative to healthy controls. Lines indicate pairing 
(refer to Table 1 for TaqMan primer-probe sets that match the transcripts). Transcripts that are upregulated in 
progressors are in red nodes and those that are downregulated in progressors are in green. (c and d) Receiver 
operating characteristic (ROC) curves depicting the performance (model fit) of RISK6, relative to the ACS 
11-gene7 and ACS 16-gene6 signatures, measured by qRT-PCR on RNA from whole blood samples collected 
from participants of the ACS cohort within one year of TB disease diagnosis (c), or 1–2 years before TB 
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The “End Tuberculosis Strategy” of the World Health Organization (WHO) aims to reduce the annual incidence 
of tuberculosis (TB) to less than 10 cases per 100,000 people by the year 20351. To achieve this goal the primary 
proposed strategy is to increase and improve efforts to find and treat individuals with active TB disease, to con-
duct universal screening of those at high risk, and to provide preventive therapy to those at risk of progressing to 
active TB disease1. There is thus a need for improved prognostic and diagnostic tests to identify those at risk of 
incident TB and those with subclinical or active TB, for appropriate treatment. The provision and management 
of TB treatment, as well as monitoring a patient’s response to treatment, also require much improvement. The 
standard 6-month regimen of treatment appears to be unnecessarily long for many patients with drug-susceptible 
TB, while insufficient to cure some patients, even in clinical trials when treatment adherence is maximized2. 
Experimental regimens tested in recent clinical trials have also been inadequate to cure treatment-refractory 
patients3. Collectively, these data support the now accepted principle that TB exists in a pathophysiological spec-
trum that spans several stages of infection, subclinical and active disease, including distinct stages of treatment 
outcome. Achieving the “End Tuberculosis Strategy” clearly depends on approaches that can place an individual 
into the stage of this spectrum such that clinical management is appropriate.
A universal, non-sputum biomarker capable of predicting progression to active TB, diagnosing disease and 
monitoring the response to TB treatment would be a major advance in the efforts to achieve the “End Tuberculosis 
Strategy”. We hypothesized that a single, parsimonious host-blood transcriptomic signature can be developed for 
all three purposes with performance criteria that meet the target product profiles for tests to predict TB progres-
sion4 and for a TB screening test5 proposed by the WHO.
We sought to discover and validate a parsimonious and robust blood transcriptomic signature with applica-
bility for predicting incident TB, as a triage test for identifying those who should be further investigated for TB 
disease, and for monitoring of TB treatment response. We explicitly set out to develop this signature for ultimate 
translation to a hand-held point-of-care platform and therefore performed all analyses, including signature train-
ing and performance assessments in all validation cohorts, by quantitative RT-PCR, using a highly standard-
ized protocol and locked-down analysis algorithm. We assessed performance of RISK6 by blind prediction as a 
prognostic test for incident TB, as a TB diagnostic in HIV-uninfected and HIV-infected individuals, including 
individuals presenting with symptoms requiring investigation for TB at primary health care centres, and as a 
treatment response biomarker. We also tested the robustness of RISK6 and report performance of RISK6 meas-
ured in capillary blood samples collected by finger-prick, facilitating the way for incorporation into point-of-care 
diagnostic devices.
Results
Prognostic performance of RISK6 in the adolescent cohort study discovery cohort. The RISK6 
signature was discovered on samples from adolescent progressors and controls (Supplementary Figure 1a) by select-
ing the smallest set of transcripts with the best prognostic performance based on qRT-PCR data. RISK6 comprises 
an ensemble of 9 transcript pairs formed between three transcripts upregulated in progressors (GBP2, FCGR1B, 
and SERPING1), and three transcripts downregulated in progressors (TUBGCP6, TRMT2A, and SDR39U1), rel-
ative to non-progressors (Supplementary Table 1 and Fig. 1a,b). We first sought to determine if the prognostic per-
formance of RISK6 for incident TB in the discovery cohort was comparable to that of the previously published ACS 
16-gene signature6, consisting of 57 transcripts (PCR primer/probe assays) or the ACS 11-gene version (48 PCR 
primer/probe assays), which was developed for greater throughput in multiplex assays7. The PCR-based RISK6 
and both ACS signatures readily discriminated between Adolescent Cohort Study progressor and non-progressor 
samples collected within 12 months of TB diagnosis (Fig. 1c). Interestingly, prognostic performance of RISK6, 
estimated by model fit (AUC 87.6%, 95%CI 82.8–92.4), was significantly better than ACS 16-gene (AUC 81.8%, 
95%CI 75.1–88.6, DeLong test p = 0.024) and ACS 11-gene (AUC 82.2%, 95%CI 75.6–88.8, DeLong test p = 0.03). 
As observed previously with the 16-gene signature6, RISK6 also discriminated between progressors and non-pro-
gressors using samples collected between 12 and 24 months before TB disease diagnosis (AUC 74.0%, 95%CI 
66.0–82.0), although discrimination was weaker than observed on samples within a year of diagnosis (Fig. 1d).
Validation of RISK6 prognostic performance in the GC6–74 cohort. We validated prognostic per-
formance of the RISK6 signature for incident TB by blind prediction on the independent GC6–74 cohorts of 
household TB contacts from South Africa, The Gambia and Ethiopia, who either progressed to TB or remained 
asymptomatic8. RISK6 significantly discriminated between GC6-74 progressors and non-progressors on samples 
collected within 12 months of incident TB diagnosis (AUC 70.6%, 95%CI 61.6–79.5) and those collected 12–24 
months before TB diagnosis (AUC 67.6%, 95%CI 58.2–76.9, Fig. 1e and Table 1). At a sensitivity threshold of 
75%, RISK6 achieved a specificity of 50.3% within 1 year of diagnosis in the GC6-74 cohort, which does not meet 
the WHO target product profile (TPP) for a test predicting progression from tuberculosis infection to active 
disease4 (Table 2).
diagnosis (d). Shaded areas depict the 95% CI. (e) Receiver operating characteristic (ROC) curves depicting 
prognostic performance, by blind prediction of RISK6, measured by qRT-PCR on RNA from whole blood 
RNA collected from participants of the GC6-74 cohort of household contacts. Shaded areas depict the 95% CI. 
(f) Prognostic performance of RISK6 for incident TB in household contacts from South Africa, The Gambia 
or Ethiopia, measured by qRT-PCR on RNA from whole blood RNA collected within 1 year of TB diagnosis 
from participants of the GC6-74 cohort. The boxes in the top left corner represent the optimal (solid line) and 
minimum (dotted line) criteria set out in the target product profile for an incipient TB test. Performance on 0–2 
years before TB diagnosis is shown in Table 1.
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We also compared RISK6 to three other signatures (ACS 16-gene, Sweeney39 and Maertzdorf410, all meas-
ured by PCR), by comparing prognostic performance for discriminating between GC6-74 progressors and 
non-progressors on samples collected within 6 months of TB diagnosis (Table 3), as previously done by Warsinske 
et al. in the ACS cohort11. Performance of the four signatures was equivalent, with AUC values ranging from 
67.6% (ACS 16-gene, 95%CI 60.2–75.0) to 71.4% (Sweeney3, 95%CI 61.2–81.7). None of the signatures met the 
minimum criteria set out in the TPP for a progression test in the GC6-74 cohort (Table 3 and Supplementary 
Figure 3).
Because RISK6 was discovered on a South African cohort it was important to determine if performance var-
ies by geography, since differences in population genetic structure, local epidemiology and environment may 
influence blood biomarker performance12. We therefore also assessed prognostic performance by country. 
Interestingly, when assessing samples collected within 12 months of TB diagnosis, the AUC was highest for the 
Gambian cohort (AUC 76.3%, 95%CI 64.4–88.1%, Fig. 1f and Table 1), while the AUC for the South African 
cohort was similar to the entire, combined GC6-74 cohort (AUC 69.9%, 95%CI 55.5–84.2, Fig. 1f). Although 
the AUC for the smaller Ethiopian cohort (comprising 12 progressors) was also similar (AUC 69.3%, 95%CI 
39.4–99.2), the confidence intervals were very large and discrimination between progressors and non-progressors 
was not significant (Fig. 1f).
Performance of RISK6 as a screening test in HIV-uninfected and HIV-infected individuals. 
Expression levels of the six transcripts in RISK6 differed most between adolescent progressors and 
non-progressors at the time of TB diagnosis (Fig. 1a). In light of this, we hypothesized that RISK6 would also 
yield good performance as a screening or triage test for TB. Since HIV infection is a major risk factor for TB 
and a large proportion of TB patients in settings endemic for TB are HIV-infected13, we aimed to determine 
diagnostic performance in both HIV-infected and uninfected individuals. We therefore compared diagnostic 
performance of RISK6, benchmarked against the ACS 11-gene signature, in 112 HIV-uninfected (61 asympto-
matic controls and 51 TB cases) and 82 HIV-infected (40 asymptomatic controls and 42 TB cases) adults from the 
Western Cape, South Africa. Excellent diagnostic performance of RISK6 was seen in both HIV-uninfected (AUC 
93.7%, 95%CI 87.9–99.4%) and HIV-infected persons (AUC 92.6%, 95%CI 86.8–98.5); performance was not 
different between the two groups (DeLong unpaired test p = 0.76, Fig. 2a). By contrast, diagnostic performance 
Gambia South Africa Ethiopia
AUC (95% CI) p AUC (95% CI) p AUC (95% CI) p
RISK6 70% (59–81) <0.0001 70% (61–79) 0.0015 66% (46–86) 0.028
ACS 16-gene 67% (56–78) 0.0016 72% (63–81) <0.0001 60% (41–79) 0.11
RISK4* 72% (55–88) 0.0054 72% (53–92) 0.0063 67% (50–83) 0.02
Table 1. Performance of RISK6 signature in the GC6 cohort by blinded validation, compared to the ACS 16-
gene and RISK4 signatures. Samples from 0–24 months before TB diagnosis were included. *In the smaller 


















samples AUC AUC 95%CI
ACS (discovery)* 0.53 82.8% 0.46 82.8% 46 284 87.6% 82.8–92.4%
GC6–74* 0.35 50.0% 0.48 56.0% 50 372 70.6% 61.6–79.5%
Table 2. Accuracy of the RISK6 signature benchmarked against the WHO target product profile for prediction 
of incident TB within 12 months of sample collection. *Samples collected within 1 year of TB diagnosis. For 
GC6-74 participants from all three countries were combined. #Specificity and the RISK6 threshold are reported 
at a sensitivity of 75%, which is the minimum criterion specified in the TPP for an incipient TB test4. At a 
sensitivity of 75%, the minimum specificity as set out in this TPP should be ≥75%. $Sensitivity and the RISK6 
threshold are reported at a specificity of 75%, which is the minimum criterion specified in the TPP for an 
incipient TB test4. At a specificity of 75%, the minimum sensitivity as set out in this TPP should be ≥75%.
GC6-74 progressor vs non-progressor
AUC 95% CI p
RISK6 70.2% 58.5–81.8% 0.0002
ACS 16-gene 67.6% 60.2–75.0% <0.0001
Sweeney3 71.4% 61.2–81.7% <0.0001
Maertzdorf4 65.7% 54.4–77.1% 0.0003
Table 3. Performance of RISK6 signature compared to the ACS 16-gene, Sweeney3 and Maertzdorf4 signatures 
in GC6-74 non-progressor vs progressor samples, collected within 6 months of TB diagnosis were included.
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Figure 2. Diagnostic performance of RISK6 as a triage test. (a and b) ROC curves depicting diagnostic 
performance of RISK6 (a) and the ACS 11-gene signature (b), for discrimination between active TB cases and 
Mtb-infected controls in HIV-negative or HIV-positive individuals. RISK6 was measured by qRT-PCR on RNA 
from whole blood. Shaded areas depict the 95% CI. The boxes in the top left corner represent the optimal (solid 
line) and minimum (dotted line) criteria set out in the target product profile for a screening/triage test for TB. 
(c) Comparison of RISK6 signature scores in Mtb-infected controls and active TB cases in HIV-negative or 
HIV-positive individuals. P-values were calculated using the Mann-Whitney U test. Horizontal lines represent 
medians; boxes represent the IQR and whiskers the range. Dots represent individual sample scores. (d) Relative 
differences in RISK6 transcript expression levels between HIV-negative and HIV-positive Mtb-infected controls 
(green) or active TB cases (orange). Dots depict medians and error bars the 95% CI, calculated from 1000 
bootstrapped Ct values. The dashed line represents zero. (e) Comparison of RISK6 signature scores, by blind 
prediction, in patients with definite TB (with rigorous microbiological confirmation), patients with probable 
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of the ACS 11-gene signature was better in HIV-uninfected (AUC 97.3%, 95%CI 93.7–100) than in HIV-infected 
persons (AUC 87.9%, 95%CI 80.6–95.2); the 9% lower AUC in HIV-infected persons was significant (DeLong 
unpaired test p = 0.027, Fig. 2b). RISK6 signature scores were higher in HIV-infected controls compared to 
HIV-uninfected controls, suggesting an effect of underlying HIV infection on RISK6 (Fig. 2c). To understand 
the effects of underlying HIV infection on the RISK6 signature, we determined the difference in expression of 
each transcript between HIV-infected and uninfected individuals. Expression of FCGR1B and GBP2, but none 
of the other transcripts, was significantly higher in HIV-infected than uninfected controls, while no significant 
differences were observed in TB cases (Fig. 2d). At a sensitivity threshold of 90%, RISK6 achieved a specificity of 
93.4% and 72.5% in HIV-uninfected and HIV-infected persons, respectively (Table 4 and Supplementary Table 2).
Diagnostic performance of RISK6 as a screening test in patients with respiratory symptoms. 
We also determined RISK6 performance as a screening test in symptomatic adults enrolled into the ScreenTB14 
and AE-TBC studies15,16. These adult participants presented at primary health care clinics in Cape Town, South 
Africa with symptoms requiring investigation for TB including coughing for >2 weeks and at least another symp-
tom consistent with TB, and were enrolled prior to the establishment of a TB or other disease diagnosis. RISK6 
signature scores were measured on blinded PAXgene blood collected at presentation for care before treatment 
initiation in (1) 76 patients with microbiologically-confirmed, definite TB, (2) 7 patients with probable TB, and 
(3) 210 patients with other respiratory diseases (ORD) (Fig. 2e, see Supplementary Table 4 for diagnostic cri-
teria). RISK6 discriminated between definite TB and ORD patients with an AUC of 84.8% (95%CI 79.6–90, 
Fig. 2f). At a sensitivity threshold of 90%, RISK6 achieved a specificity of 55.7% (95%CI 32.9–76.7) in these 
symptomatic patients (Table 4 and Supplementary Table 2), which falls short of the WHO target product profile 
for a community-based triage or referral test to identify people suspected of having TB5. RISK6 performance did 
not differ between HIV positive and negative participants (HIV-neg, n = 250: AUC 85.4%, 95%CI 79.7–91.0; 
HIV-pos, n = 36: AUC 79.5%, 95%CI 65.1–94.0, DeLong unpaired test p = 0.46, data not shown).
We unpacked the performance of RISK6 further in posthoc analyses performed after unblinding of patient 
diagnostic status. We noted that a considerable number (n = 121) of ScreenTB and AE-TBC participants had 
a record of least one previous episode of TB; this is typical of patients presenting for TB investigation in such 
high-incidence settings13. RISK6 discriminated between definite TB and ORD among participants with no history 
of prior TB with an AUC of 87.2% (95%CI 80.2–94.1%), whereas in those with a history of prior TB the AUC was 
82.7% (95%CI 74.6–90.7%, Table 4, Fig. 2g). Although these AUCs were not statistically different, the specificities 
at a set sensitivity of >90% were markedly different at 75.0% and 37.8%, respectively (Table 4).
We also applied RISK6 to published microarray datasets, using RISK6geo, a risk score algorithm adapted for 
application to microarray or RNA-seq data, which is different to the RISK6 algorithm used throughout the man-
uscript when computing the RISK6 score from PCR data. RISK6geo discriminated between TB cases and asymp-
tomatic M.tb-infected controls with AUCs exceeding 88% in all cohorts (Supplementary Table 3). To understand 
how these two score algorithms may differ, we compared performance characteristics of RISK6 and RISK6geo 
on qRT-PCR data from the different cohorts in this study. AUCs obtained with the two score algorithms were 
extremely similar and highly correlated (Spearman ρ > 0.96, Supplementary Table 2).
Performance of RISK6 as a TB treatment monitoring biomarker. Diagnostic performance of RISK6 
was also assessed in the Catalysis cohort of TB patients who were studied during and after TB treatment17–19. 
RISK6 achieved an AUC of 93.5% (95%CI 85.5–100) for discriminating between newly diagnosed TB cases and 
asymptomatic controls (Fig. 3a). Next, we determined if RISK6 has utility as a biomarker for monitoring TB 
treatment. We hypothesized that RISK6 scores, which are very high in patients with active disease, would decrease 
rapidly during TB treatment such that samples collected after bacteriological cure can be discriminated from the 
respective pre-treatment sample with high accuracy. We also hypothesized that RISK6 would allow discrimina-
tion of cured patients from those with treatment failure after 24 weeks of treatment. When measured by qRT-PCR 
in patients with bacteriological cure in the Catalysis cohort, RISK6 scores decreased significantly during TB 
treatment, although scores observed at the end of treatment were still significantly higher than those observed 
in healthy controls (Fig. 3b), as reported for the 16-gene ACS signature previously19. Despite this, RISK6 signif-
icantly discriminated between samples collected pre-treatment and one week after treatment initiation (AUC 
79.5%, 95%CI 72.2–86.7), four weeks after treatment initiation (AUC 77.4%, 95%CI 69.9–84.9) and end of treat-
ment samples (AUC 88.1%, 95%CI 82.5–93.6; (Fig. 3c). Importantly, RISK6 was a strong predictor of treatment 
outcome and significantly differentiated between the 78 patients with bacteriological cure and the 7 patients with 
treatment failure even before treatment initiation (time of TB diagnosis, AUC 77.1, 95%CI 52.9–100, Fig. 3d), 
and at the end of treatment (AUC 95.2, 95%CI 87.5–100, Fig. 3d). These data are consistent with RISK6 detecting 
differences in inflammatory profiles before the initiation of treatment which predict the outcome of treatment, 
while also detecting ongoing inflammation in those who fail treatment and do not achieve bacteriological cure 
TB and in patients with other respiratory diseases (ORD). Horizontal lines depict medians, boxes the IQR 
and the whiskers the range. Violin plots depict the density of data points. P-values were computed by Mann-
Whitney U test. (f) Receiver operating characteristic (ROC) curve depicting discrimination between diagnostic 
performance, by blind prediction of RISK6, measured by qRT-PCR in definite TB patients and patients 
with other respiratory diseases (ORD). Shaded areas depict the 95% CI. (g) ROC curves depicting RISK6 
discrimination between definite TB and ORD participants of the ScreenTB and AE-TBC cohorts stratified into 
participants with no history of prior TB (black), or in those with a history of prior TB (red). Shaded areas depict 
the 95% CI.
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by 24 weeks. To address this further, we determined if blood RNA signature scores were associated with in vivo 
pulmonary inflammation measured by 18F-labeled fluorodeoxyglucose (18F FDG) PET-CT. Surprisingly, RISK6 
scores directly correlated with metabolic activity in lung lesions as measured by total glycolytic activity index 
(TGAI) (Spearman ρ = 0.66, p < 0.0001, Fig. 3e), while signature scores correlated inversely with Xpert Ct values 
(Spearman ρ = −0.60, p < 0.0001) and Mycobacterial Growth Indicator Tube (MGIT) culture days-to-positivity 
values (Spearman ρ = −0.67, p < 0.0001) measured at TB diagnosis (data not shown).
Performance of RISK6 as triage test and TB treatment monitoring biomarker in South American 
Cohorts. An important issue is how a biosignature that was trained and validated in African cohorts will 
perform in geographically distinct populations. To address this, we assessed diagnostic performance of RISK6 
measured by qRT-PCR in cohorts from Peru and Brazil. In the Peruvian cohort, RISK6 discriminated between 
culture-positive TB patients and QFT-negative asymptomatic controls with an AUC of 91.5% (95%CI 86.2–96.9, 
Fig. 4a) and between TB patients and QFT-positive asymptomatic controls with an AUC of 89.6% (95%CI 83.5–
95.7, Fig. 4b). RISK6 also achieved an AUC of 90.9% (95%CI 85.2–96.6) for discriminating between Brazilian 
culture-positive TB patients and close contacts (Fig. 4c). The minimum criteria for a screening or triage test for 
TB, set out by the WHO, set the sensitivity at ≥90% at a specificity of 70%5. With sensitivity at ≥90%, perfor-
mance of RISK6 in the South American cohorts met these criteria when discriminating between TB cases and 
QFT-negative controls, but discrimination between TB cases and QFT-positive controls fell short of the 70% 
specificity mark (Table 4 and Supplementary Table 2). It was notable that the RISK6 score threshold at which 
the sensitivity was ~90% was quite variable, suggesting that the positivity cut-off for a signature that predicts 
incident TB, detects prevalent TB, or monitors treatment response, may have to be different. The epidemiological 
setting and design features of each cohort, as well as experimental variability in the laboratory are likely to have 
contributed to the different thresholds we observed, highlighting the need for additional assay qualification. We 
note that the much lower threshold for the Peruvian cohort was because RISK6 was measured on RNA extracted 
from PBMC (not whole blood), which was previously shown to reduce transcriptomic signature scores, although 
discrimination between TB and controls was not affected7.
We also determined performance of RISK6 as a biosignature for monitoring TB treatment in the Brazilian 
patients, all of whom achieved microbiological cure after 6 months of treatment. RISK6 scores decreased signif-
icantly after 8 weeks of TB treatment and, unlike the Catalysis cohort, scores observed in the Brazilian patients 
at the end of treatment had reached levels observed in healthy controls (Fig. 4d,e). RISK6 also significantly dis-
criminated between samples collected pre-treatment and 8 weeks after treatment initiation (AUC 69.2%, 95% CI 
58.6–79.7), and end of treatment samples (AUC 87.3%, 95% CI 79.9–94.6, Fig. 4f).
RISK6 as a treatment biomarker in HIV-infected patients with recurrent TB. The promising 
results from these treatment response studies prompted us to also evaluate if RISK6 can monitor success of 
recurrent TB treatment in HIV-infected individuals on ART, who participated in the randomized controlled 
IMPRESS trial. IMPRESS determined if a retreatment regimen that contained moxifloxacin, instead of ethambu-
tol, would improve TB retreatment outcomes relative to the standard regimen20. No differences in RISK6 scores 
were observed between the two treatment arms of the trial (data not shown). Consequently, all analyses were per-
formed with the treatment arms combined. RISK6 scores decreased upon treatment (Fig. 5a) and could discrim-
inate significantly between samples collected at the pre-treatment time point (baseline) and those collected after 











TB (Definite TB vs 
asymptomatic controls)
HIV+ 0.78 90.5% 72.5% 42 40 92.6% 86.8–98.5%
HIV− 0.78 90.2% 93.4% 51 61 93.7% 87.9–99.4%
ScreenTB and AE-TBC: 
Symptomatic adults 
(Definite TB vs ORD)
A-priori analysis 0.55 90.8% 55.7% 76 210 84.8% 79.6–90.0%
$Post-hoc analysis in those 
without previous TB 0.61 91.0% 75% 37 128 87.2% 80.2–94.1%
$Post-hoc analysis in those 
with previous TB 0.46 92.3% 37.8% 39 82 82.7% 74.6–90.7%
RePORT-Brazil (Definite 
TB vs household contacts)
Definite TB vs combined 
QFT+ and QFT− 0.61 90.2% 73.7% 51 99 90.9% 85.2–96.6%
Definite TB vs QFT+ 0.61 90.2% 59.1% 51 22 88.6% 81.2–96%
Definite TB vs QFT− 0.61 90.2% 77.9% 51 77 91.5% 85.9–97.1%
Peru (Definite TB vs 
household contacts)
Definite TB vs combined 
QFT+ and QFT− 0.21 91.7% 65.6% 48 96 90.6% 85.5–95.6%
Definite TB vs QFT+ 0.21 91.7% 57.1% 48 49 89.6% 83.5–95.7%
Definite TB vs QFT− 0.19 91.7% 74.5% 48 47 91.5% 86.2–96.9%
Catalysis Cohort (Definite TB vs asymptomatic 
controls) 0.39 90.0% 95.2% 87 21 93.9% 85.5–100%
Table 4. Accuracy of the RISK6 signature benchmarked against the WHO target product profile for a 
screening/triage test. #Specificities and the RISK6 threshold are reported at a sensitivity of ~90%, which is 
the minimum criterion specified in the TPP for an incipient TB test4. At a sensitivity of ~90%, the minimum 
specificity as set out in this TPP should be ≥70%. $Posthoc performance assessed after sample unblinding.
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Figure 3. Treatment monitoring using the RISK6 signature in the Catalysis TB Treatment Cohort. (a) ROC 
curve depicting diagnostic performance of RISK6 for discriminating between active TB cases (irrespective of 
treatment outcome), sampled prior to treatment initiation (baseline, n = 87), and controls (n = 21) from the 
Catalysis Cohort. Shaded areas depict the 95% CI. The boxes in the top left corner represent the optimal (solid 
line) and minimum (dotted line) criteria set out in the target product profile for a screening/triage test for TB. 
(b) Comparison of RISK6 signature scores in cases (irrespective of treatment outcome) from the Catalysis 
Cohort at baseline and week 1 or week 4 after treatment initiation and after treatment completion (EoRx). Also 
shown are the RISK6 signature scores in healthy controls. Horizontal lines depict medians, the boxes the IQR 
and the whiskers the range. Violin plots depict the density of data points. The p-value, computed by Mann-
Whitney U test, compares RISK6 signature scores after treatment completion with those in controls. (c) ROC 
curves depicting performance of RISK6 for discriminating between baseline (pre-treatment) samples and 
samples collected after week 1, week 4 or completion of TB treatment. (d) Prediction of treatment failure using 
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baseline samples and those collected at the end of treatment, when all patients had achieved clinical cure, was bet-
ter than after 2 months of treatment (AUC 91.2%, 95%CI 86.0–96.3, Fig. 5b), although inflammation appeared to 
resolve further after the end of treatment, since RISK6 discriminated best between baseline and samples collected 
6–8 months after treatment completion (AUC 98.5%, 95%CI 96.5–100, Fig. 5b). When measured at baseline (not 
shown) or the end of the intensive treatment phase at 2 months (AUC 63.4%, 95%CI 48.2–78.5), RISK6 did not 
discriminate significantly between patients who had sputum culture conversion at 2 months and those who con-
verted after 2 months (Fig. 5c). It was not possible to determine if RISK6 could predict treatment failure in this 
trial since all patients achieved bacteriological cure.
Although HIV infection causes immunodeficiency, it also drives chronic immune activation and inflam-
mation21–23 and induces expression of type I IFN response, including interferon stimulated genes (ISGs)24,25. 
Successful antiretroviral therapy (ART) suppresses viral replication and reduces plasma viral load (pVL), decreas-
ing inflammation and immune activation, although not to levels typical of HIV-uninfected persons26. Since 
RISK6 includes three IFN-inducible ISG transcripts, we aimed to evaluate the effect of pVL on signature scores 
in the IMPRESS trial. Eighty-five participants had pVL measurements, 36 with detectable viral loads (above 
400 copies per mL) and 49 with undetectable viral loads (below 400 copies per mL); sixty of the measurements 
were baseline samples and 25 were end-of-treatment samples. RISK6 signature scores were significantly higher 
in samples with detectable pVL than those with undetectable pVL (p = 0.0027, Fig. 5d), showing that pVL is a 
confounder in ISG-containing transcriptomic signatures.
Robustness of the PCR-based RISK6 signature. An advantage of the pair-wise ensemble structure 
of RISK6 is that a signature score can be calculated even if one or more transcript is not detected, for example 
due to a failure during PCR amplification. To determine how robust the signature is to such missing data, we 
compared diagnostic performance for discriminating between HIV-uninfected TB cases and asymptomatic con-
trols (Fig. 2) by the full 6-gene RISK6 signature, which comprises nine pairs formed between six transcripts, or 
after removing one, two, three or four, of these transcripts such that every combination of the pairs was tested. 
Diagnostic performance was not affected by removal of a single transcript, irrespective of transcript identity 
(AUC for full RISK6: 93.6%, 95%CI 87.4–99.7; average AUC for 5-transcript signature: 93.2%, lower 95%CI 
bound: 85.5, Fig. 6a). However, removal of two or more transcripts, especially when two or more of SERPING1, 
SDR39U1 or TUBGCP6 were omitted, resulted in somewhat decreased performance of RISK6 (average AUC for 
4-transcript signature: 92.4%, lower 95%CI bound: 80.1; average AUC for 3-transcript signature: 91.4%, lower 
95%CI bound: 72.1). A very similar result was observed when the same analysis was performed on the Brazilian 
cohort (Supplementary Figure 4). These results show that RISK6 can tolerate one or even two missing transcripts 
without the diagnostic performance being markedly eroded.
Effective deployment of transcriptomic signature tests such as RISK6 in community or primary health care 
settings is dependent on successful translation of gene expression quantification to methods that are simple, 
cheap and rapid. An expensive and cumbersome component of any blood transcriptomic assay is the procedure 
and cost of blood collection. Therefore, we sought to determine if RISK6 could be reliably measured in very small 
volumes of capillary blood collected by finger stick. We compared discrimination between healthy controls and 
TB cases by RISK6, measured by qRT-PCR in 20 μL, 50 μL or 100 μL capillary blood, benchmarked against the 
typical 2.5 mL venous blood collected in PAXgene tubes. Among samples collected from the 49 participants, the 
number of samples with one or more failed PCR reaction, where the amplification curve for one transcript did not 
pass the QC threshold defined by Fluidigm, for the 20 μL, 50 μL and 100 μL capillary blood volumes was 4 (8%), 
3 (6%) and 3 (6%), respectively. None of the 2.5 mL venous blood samples yielded failed PCR reactions. When 
failure of 1 of the 6 transcripts was tolerated, RISK6 scores could be calculated for 98% (1 failed sample), 98% and 
100% of the 20 μL, 50 μL and 100 μL capillary blood samples, respectively.
RISK6 signature scores measured on 2.5 mL venous blood correlated strongly with those measured on 20 μL, 
50 μL or 100 μL capillary blood samples (Spearman ρ > 0.83; Fig. 6b–d). Diagnostic performance of RISK6 was 
statistically non-inferior when measured in 20 μL, 50 μL or 100 μL capillary blood samples compared with venous 
blood; ROC analysis yielded equivalent AUC curves (Fig. 6b–d). These results show that RISK6 can be measured 
on very small volumes of capillary blood collected by finger stick, which may be amenable to translation to a point 
of care testing platform.
Discussion
We discovered and validated RISK6, a parsimonious and robust blood transcriptomic signature with applicability 
for predicting incident TB, as a triage test for identifying individuals with or without respiratory symptoms who 
should be further investigated for TB disease, and for monitoring the response to TB treatment.
RISK6 identified individuals at risk of progression to incident TB and statistically validated in the independent 
GC6-74 cohort of TB household contacts by blind prediction. When applied to samples collected within 1 year 
of TB diagnosis in the ACS discovery cohort, RISK6 met the minimum criteria for a test for progression to TB 
set out by the WHO and FIND4. However, when applied to samples collected within 1 year of TB diagnosis in the 
GC6-74 validation cohort, the specificity at a sensitivity of ≥75% was 50.3%, which did not meet these criteria 
(Table 2). Prognostic performance for incident TB of RISK6 was significantly better than that reported for the 
RISK6. ROC curves depict discrimination between cases with cure (n = 70) and those with treatment failure 
(n = 7) in samples collected at treatment initiation (Baseline, red), at week 1 (blue), week 4 (green) and after 
treatment completion (EoRx, black). (e) RISK6 scores plotted versus total glycolytic activity index measured by 
PET-CT for all available samples.
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Figure 4. Diagnostic performance and treatment monitoring in South American cohorts. (a-b) ROC curve 
depicting diagnostic performance of RISK6 for discriminating between (a) culture-positive active TB cases 
(n = 48) and QuantiFERON-negative controls (n = 47), or between (b) culture-positive active TB cases (n = 48) 
and QuantiFERON-positive controls (n = 49) from the Peru Cohort. Shaded areas depict the 95% CI. The boxes 
in the top left corner represent the optimal (solid line) and minimum (dotted line) criteria set out in the target 
product profile for a screening/triage test for TB. (c) ROC curve depicting diagnostic performance of RISK6 
for discriminating between culture-positive active TB cases, sampled prior to treatment initiation (baseline, 
n = 51), and controls (n = 99) from the RePORT-Brazil Cohort. (d) Comparison of RISK6 signature scores in 
TB cases at baseline, week 8 after treatment initiation and after treatment completion (Post Rx). Also shown 
are the RISK6 signature scores in healthy controls from Brazil. Horizontal lines depict medians, the boxes 
the IQR and the whiskers the range. Violin plots depict the density of data points. The p-value, computed by 
Mann-Whitney U test, compares RISK6 signature scores after treatment completion with those in controls. (e) 
1 1Scientific RepoRtS |         (2020) 10:8629  | https://doi.org/10.1038/s41598-020-65043-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
previously described 16-gene ACS signature6, which was discovered by RNA-seq also in the ACS progressor 
and non-progressor cohort. Ability to discriminate between GC6-74 non-progressors and progressors within 
6 months of TB diagnosis was not different between RISK6 and the ACS 16-gene, Sweeney3 and Maertzdorf4 
signatures, suggesting that these signatures detect similar biological processes that occur during disease progres-
sion. None of these signatures met the minimum TPP criteria for a progression test in the GC6-744. The marked 
reduction in signature performance between ACS and GC6-74 was a notable result. Since these four signatures 
showed very similar performance in the GC6-74 cohort, we posit that it is most likely due to differences in age, 
epidemiology, study design and other factors between the cohorts. We also cannot exclude the possibility that 
reinfection with M.tb in some of the ACS participants, who reside in a setting of a very high force of infection27, 
may have contributed to rapid disease progression, leading to a stronger transcriptomic signal.
Our findings are consistent with recent work from Gupta et al., who systematically compared the prognostic 
performance of 17 published host-derived transcriptional signatures in a RNA-seq dataset that combined 4 pro-
gressor and controls cohorts, which included the ACS and GC6-74 cohorts28. Despite the heterogeneity of cohorts 
and study designs used to derive these signatures, eight signatures including ACS 16-gene, Sweeney3 and RISK4 
performed equivalently. Similarly, Warsinske et al. reported a comparison of 16 signatures for diagnostic perfor-
mance in 24 datasets from TB cases and controls11. They found that two signatures (Sweeney39 and Sambarey1029) 
met the TPP criteria for a triage test in data restricted to patients with culture-confirmed diagnosis of TB. Such 
head-to-head comparisons of different transcriptomic signatures are extremely valuable to allow unbiased selec-
tion of the best performing signatures for further evaluation.
Performance of RISK6 in the distinct cohorts from 3 different African countries was similar, although RISK6 
did not significantly discriminate between progressors and non-progressors from Ethiopia, likely due to the small 
number of progressors, namely 12. The limitations of such small sample sizes for biomarker validation is also 
evident from other biomarker studies on the GC6-74 cohort and it was notable that the performance of RISK6 
in the three GC6-74 cohorts was very similar to the previously published RISK4 signature (Table 2), which was 
specifically developed as a “pan-African signature”8. Recent studies showed that the 16-gene ACS signature, as 
well as the other small diagnostic Sweeney3 and Maertzdorf4 signatures, did not validate in either one or both 
of the GC6-74 validation sub-cohorts of Gambian or Ethiopian progressor and non-progressor TB household 
contacts8. However, when the 16-gene ACS signature was measured in the full GC6-74 cohort from The Gambia, 
comprising 30 progressors and 129 non-progressors6, the signature significantly validated by blind prediction. 
These results highlight the value of longitudinal cohort studies with sufficient incident TB cases to allow reliable 
assessment of prognostic performance of risk signatures. It is critical that more such cohort studies be performed 
to increase our collective capacity to develop, refine and validate such biomarkers.
A reliable and simple triage test to identify those who should be investigated more intensively for subclinical 
or active TB disease is urgently needed to improve case finding strategies and allow earlier diagnosis and treat-
ment. RISK6 also performed well as a triage test in patients with respiratory symptoms who presented for care. 
However, with 56% specificity at >90% sensitivity, it did not meet the minimum criteria set out in the WHO tar-
get product profile (TPP) for a referral test to identify people who may have TB5. However, in our post-hoc anal-
yses the specificity of RISK6 in differentiating between definite TB cases and ORD among patients with no prior 
history of TB was 75% at a set sensitivity of >90% (Table 4), which met the WHO target product profile (TPP). 
Data regarding the interval since the previous TB episode was often unavailable, precluding analysis of this factor. 
This finding highlights the importance of including clinical and epidemiological factors in studies of diagnostic 
biosignatures. Community-based case finding studies and prevalence surveys have shown that a substantial pro-
portion of microbiologically-confirmed TB cases are asymptomatic30–32, highlighting the need for TB case finding 
in asymptomatic communities. Definitive diagnoses of ORD patients were not determined in the ScreenTB and 
AE-TBC study, but larger future studies with careful diagnoses of patients with ORD would be essential to evalu-
ate the specificity of RISK6, and define respiratory diseases most difficult to differentiate from TB.
RISK6 showed excellent diagnostic performance in differentiating between symptomatic TB cases and asymp-
tomatic controls in four different case-control cohorts from South Africa, Peru and Brazil. Application of RISK6 
to the South African cohorts met or exceeded the sensitivity and specificity criteria set out in the TPP for a 
screening or triage test5. In the South American cohorts, however, these criteria were only met when TB cases 
were compared to uninfected controls as determined by negative QuantiFERON tests. Whether this reflects a real 
geographic, genetic, environmental or epidemiological difference between South African and South American 
communities is not clear. For the Peruvian cohort RISK6 measurements were performed on RNA isolated from 
PBMC, which may have affected diagnostic performance, although we showed that near-identical ROC AUC 
results were observed when diagnostic performance of the ACS 11-gene signature was measured in whole blood 
and PBMC7. It is noteworthy that diagnostic performance of RISK6 was higher in Brazilian culture + smear + TB 
cases (AUC 99.8%, 95%CI 99.4–100) than in culture+smear- TB cases (AUC 90.5%, 95%CI 76.8–100) and that 
RISK6 scores correlated significantly with lung lesion activity measured by PET in the South African Catalysis 
cohort. RISK6 scores also decreased during disease resolution upon TB treatment and showed promise as a treat-
ment response biomarker. This reflects the opposite of the increasing inflammatory signals detected by RISK6 
during disease progression, as previously reported for other transcriptomic signatures19. Our findings strongly 
ROC curves depicting performance of RISK6 for discriminating between healthy control samples and samples 
collected from TB cases before treatment initiation (baseline), at week 8 after treatment initiation, or completion 
of TB treatment (Post Rx). (f) ROC curves depicting performance of RISK6 for discriminating between baseline 
samples from TB cases and samples collected 8 weeks after treatment initiation, or upon completion of TB 
treatment (Post Rx).
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suggest that disease severity in TB cases plays a role in performance of transcriptomic signatures, as reported 
previously for other signatures19,33, and likely other biomarkers. Given the lines of evidence that such signatures 
track severity of disease and lung lesions, it should be noted that biomarker performance in populations from dif-
ferent settings may be influenced by differences in study design that may preferentially enrol patients with more 
or less severe disease, rather than reflecting purely geography-associated differences. Larger and well-designed 
longitudinal biomarker studies are necessary to investigate the performance characteristics of blood biomarkers, 
such as RISK6, for classifying individuals with ambiguous respiratory phenotypes that are difficult to diagnose, 
and for revealing which stage of the TB spectrum such individuals may fall into.
Underlying HIV-infection did not significantly affect diagnostic or treatment response performance of RISK6, 
which is crucial given the high prevalence of undiagnosed TB in people living with HIV13. We acknowledge 
Figure 5. Treatment monitoring using the RISK6 signature in the IMPRESS cohort. (a) Comparison of RISK6 
signature scores in HIV-infected TB cases (irrespective of treatment outcome) from the IMPRESS cohort at 
baseline, month 2 after treatment initiation, at treatment completion (EoRx) and 6–8 months after treatment 
completion (Post Rx). Horizontal lines depict medians, the boxes the IQR and the whiskers the range. Violin 
plots depict the density of data points. (b) ROC curves depicting performance of RISK6 for discriminating 
between baseline (pre-treatment) samples and samples collected at month 2 after treatment initiation, at 
treatment completion (EoRx) and 6–8 months after treatment completion (Post Rx). Shaded areas depict the 
95% CI. The boxes in the top left corner represent the optimal (solid line) and minimum (dotted line) criteria 
set out in the target product profile for a screening/triage test for TB. (c) ROC curve depicting performance 
of RISK6, measured at 2 months on TB treatment, for discriminating between TB cases who converted their 
sputum to negative by 2 months (early converters) and those who converted after 2 months. (d) Comparison 
of RISK6 signature scores in IMPRESS participants stratified by detectable (>400 RNA copies/mL plasma) vs. 
undetectable plasma HIV load (<400 RNA copies/mL plasma). Horizontal lines depict medians, the boxes 
the IQR and the whiskers the range. Violin plots depict the density of data points. The effect size is the relative 
difference in median plasma viral load and the p-value was calculated using Mann-Whitney U test.
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that the effect of HIV was not assessed in all of the validation cohorts and more such analyses are necessary 
to definitively establish the effects of underlying HIV infection on RISK6 performance. Regardless, other pub-
lished blood-based transcriptomic TB signatures showed reduced diagnostic performance in HIV-infected 
compared to uninfected persons6,9,26–28. Since most transcriptomic TB signatures detect the elevation of ISG 
expression during TB, this effect of HIV is not surprising given that strong Type I IFN responses constitute the 
typical anti-viral response34. Persistent HIV viremia also drives chronic immune activation35 which is charac-
terised by high ISG expression. Our data show that HIV-infection was associated with elevated RISK6 signature 
scores, but that expression levels of individual transcripts in the signature were not dramatically modulated by 
HIV-infection. Although discrimination between HIV-infected TB cases and controls was not diminished rela-
tive to HIV-uninfected people, our results show that a different diagnostic test threshold would likely be required 
for HIV-uninfected and HIV-infected populations. A limitation of our analyses of HIV effects is that the clinical 
studies were not sufficiently powered to investigate the performance of RISK6 in samples with detectable or high 
Figure 6. Robustness of RISK6. (a) ROC AUC values for discrimination between HIV-uninfected TB cases 
and asymptomatic controls in the CTBC cohort by the full 6-gene RISK6 signature (9 pairs formed between 
6 transcripts, far left), or after removing 1, 2, 3 or 4 of the transcripts such that every combination of the pairs 
(represented by individual blue dots) was tested. The grey bar graph represents the mean and the error bar the 
95% CI. (b–d) ROC curves depicting performance of RISK6 for discriminating between TB cases and controls 
in the capillary blood cohort. Green curves represent RISK6 measured on 2.5 mL venous blood collected in 
PAXgene tubes. Blue curves represent RISK6 measured on 20 μL (b), 50 μL (c) or 100 μL (d) capillary blood 
collected by finger stick. Shaded areas depict the 95% CI. The Spearman correlation coefficients and associated 
p-values for comparison of RISK6 scores measured by 2.5 mL venous blood versus each capillary blood volume 
are shown. Only individuals with paired venous and capillary blood results were included in each comparison 
(i.e. venous blood results in those with a missing capillary blood value were excluded from each graph). ROC 
curves were compared using the DeLong paired test in R and resulting p-values are shown.
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pVLs. The issue of limited power will be addressed in a prospective, multicohort study currently underway in 
South Africa by performing a head-to-head comparison of performance of RISK6 with other signatures, in both 
HIV-uninfected and HIV-infected persons (clinicaltrials.gov NCT02735590). Our work suggests that underlying 
HIV infection has a marked effect on performance of IFN response signatures, which requires further exami-
nation. Of note, Esmail, Wilkinson and colleagues demonstrated that a transcriptomic TB signature based on 
complement pathway genes may have greater utility in ART naïve HIV-infected persons36. In their study, pVL 
did not affect circulating immune complexes, which were associated with transcripts involved in the complement 
pathway.
We found that RISK6 scores correlated significantly with lung lesion activity measured by PET-CT in TB 
patients of the Catalysis study who underwent TB treatment. RISK6 showed good performance as a treatment 
response biomarker, decreasing in score during successful treatment and showing very good discrimination 
between pre-treatment and post-treatment samples in patients with clinical cure, even in patients with underly-
ing HIV-infection. Similar utility as a treatment response biomarker was observed in the Brazilian cohort and the 
South African Catalysis cohort. Importantly, in the Catalysis cohort RISK6 significantly predicted treatment fail-
ure prior to treatment initiation and differentiated between treatment failures and cured patients with very high 
accuracy at the end of treatment. These findings suggest that RISK6 detects inflammatory signals associated with 
the TB disease process in the lungs or other affected sites and that resolution of these processes can be tracked by 
monitoring gene expression in the blood. Our data provide proof of concept that RISK6 allows treatment moni-
toring, as has been shown for a number of other transcriptomic signatures19,33,37,38.
We explicitly developed RISK6 with the ultimate objective of translation to a hand-held point-of-care platform 
and therefore conducted all performance analyses, including the training and all validation cohorts, by qRT-PCR 
using a standardized protocol and locked-down analysis algorithm. The RISK6 score is computed based on an 
ensemble of nine transcript pairs using the pair-ratio approach, which uses ratios of transcripts regulated in 
opposite directions during TB progression, as previously described8,11,36,37. This pair-ratio feature of RISK6 elim-
inates the need for standardisation of gene expression using reference (or housekeeper) transcripts, restricting 
measurement of the signature to six primer-probes and simplifying data processing steps. Importantly, RISK6 was 
measured by a highly standardized, locked-down protocol in our studies. Consequently, RISK6 performance was 
not subject to the gene expression normalization methods that are typically necessary to overcome reproducibility 
problems due to sample and batch effects associated with microarray and RNA-sequencing data39,40. Regardless, 
to allow measurement of RISK6 scores in public microarray or RNA-sequencing datasets, we also provide the 
score computation algorithm, “RISK6geo”, which computes virtually equivalent scores to the RISK6 algorithm 
from qRT-PCR data. Finally, we showed that RISK6 could be measured on very small volumes of capillary blood 
collected by fingerstick, with no discernible effect on signature performance.
Our results support work towards incorporation of RISK6 into rapid, capillary-blood-based point-of-care 
devices for field evaluation in community and primary care settings and implementation studies.
Methods
We developed the transcriptomic signature of risk, RISK6, using samples collected from participants of the 
Adolescent Cohort Study (Supplementary Figure 1a). RISK6 was then applied to seven external validation 
cohorts to determine prognostic and diagnostic performance and utility as a treatment response biomarker 
(Supplementary Figure 1b). Most of these cohorts have been described previously6,8,19,41,42.
Adolescent cohort study (ACS) (RISK6 discovery). The Adolescent Cohort Study, including selection 
of progressors and non-progressors, was previously described6,8,41. Briefly, among 6,363 healthy adolescents from 
the Worcester region of the Western Cape, South Africa, who were enrolled, 46 “progressors” were either TST 
or QuantiFERON TB-Gold In-Tube assay (Qiagen) (QFT)-positive and developed microbiologically-confirmed 
intrathoracic disease during 2 years of follow-up. Individuals who were TST or QFT-positive at enrolment and 
remained healthy (no TB disease) during follow-up, and matched the progressors for age, gender, ethnicity, school 
of attendance and prior history of TB disease, were included as “non-progressors”. Participants were excluded if 
they developed tuberculosis disease within 6 months of enrolment (or the first TST or IGRA-positive sample) 
to exclude early asymptomatic disease that could have been present at the time of assessment, or if they were 
HIV-infected. Longitudinally collected PAXgene samples were available from most participants at six-monthly 
intervals. The Human Research Ethics Committee of the University of Cape Town approved the study (045/2005) 
and all participants provided written, informed assent, while parents or legal guardians provided written, 
informed consent. All research was performed in accordance with relevant guidelines/regulations.
GC6-74 cohort (prognostic validation). The Grand Challenges 6–74 project was previously described6,8,43. 
Briefly, HIV-uninfected household contacts of TB cases were longitudinally followed for up to 2 years, with assess-
ments at baseline, at 6 months and at 18 months. TB progressors who developed microbiologically confirmed 
TB during follow-up were retrospectively identified and matched 1:4 to healthy non-progressors. Individuals 
in whom TB disease developed within 3 months of baseline were excluded. PAXgene samples collected from 
26 Gambian progressors and 116 non-progressors, 41 South African progressors and 164 non-progressors, 
and 12 Ethiopian progressors and 48 non-progressors were included. Participants provided written, informed 
consent. Protocols were approved by the Joint Medical Research Council and Gambian Government Ethics 
Review Committee, Banjul, The Gambia (SCC.1141vs2), the Stellenbosch University Institutional Review Board 
(N05/11/187) and the Armauer Hansen Research Institute (AHRI) / All Africa Leprosy, TB and Rehabilitation 
Training Center (ALERT) Ethics Review Committee (P015/10). All research was performed in accordance with 
relevant guidelines/regulations.
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Cross-sectional TB cohort (CTBC, Diagnostic validation). Adults with newly diagnosed active 
TB (sputum Xpert MTB/RIF-positive or liquid culture-positive) were recruited at primary healthcare clinics 
in Worcester and Masiphumelele, South Africa. Asymptomatic community controls were recruited from the 
Worcester or Masiphumelele areas. HIV-infection was diagnosed with the Determine HIV1/2 test (Alere). 
Protocols were reviewed and approved by the Human Research Ethics Committee of the Faculty of Health 
Sciences at the University of Cape Town (HREC 126/2006 and HREC 288/2008). All study participants provided 
written informed consent and all research was performed in accordance with relevant guidelines/regulations.
Participants included 112 HIV-uninfected adults (51 TB cases and 61 asymptomatic controls) and 82 
HIV-infected (42 TB cases and 40 asymptomatic controls). Blood was collected in PAXgene tubes at diagnosis in 
TB cases and at enrolment in asymptomatic controls.
ScreenTB and AE-TBC cohorts (Diagnostic validation). Adults aged >18 years who presented at pri-
mary health care clinics in Cape Town or emergency or medical wards of Tygerberg Hospital in Cape Town 
with respiratory symptoms compatible with TB, including cough for at least 2 weeks and another symptom 
including fever, weight loss, haemoptysis or night sweats, were screened for inclusion for the ScreenTB14 or 
the African-European Tuberculosis Consortium (AE-TBC) studies15,16. Those who had TB treatment within 
90 days, received immunosuppressive medication (ScreenTB) or quinolones or aminoglycosides in the past 60 
days (AE-TBC), had a record of alcohol or drug abuse or a haemoglobin level <9 g/dL (ScreenTB) or <10 g/dL 
(AE-TBC), or who were pregnant or breastfeeding, where not eligible. HIV-infection was not an exclusion cri-
terion. Using a pre-defined TB classification algorithm15 (Supplementary Table 4), patients with microbiologi-
cally confirmed pulmonary TB were classified as having definite TB (n = 76). Those with either a single positive 
sputum smear or with chest radiographs that were compatible with pulmonary TB and who responded to TB 
treatment were classified as probable TB (n = 7). Patients whose sputum tested negative, and who were not started 
on TB treatment were classified as having “other respiratory diseases” (ORD, n = 210). These ORD patients also 
did not have a TB diagnosis during 2 months further follow-up. We also performed a post-hoc analysis after 
unblinding, where study particpants were grouped into those with a previous history of TB (TB cases, n = 39; 
ORD, n = 82) and those without a previous history of TB (TB cases, n = 37; ORD, n = 128). All study participants 
provided written, informed consent. The documents for the ScreenTB and AE-TBC studies were approved by the 
Health Research Ethics Committee at Stellenbosch University and all research was performed in accordance with 
relevant guidelines/regulations. Blood was collected in PAXgene tubes at enrolment, before treatment initiation.
Peruvian household contacts cohort (Diagnostic validation). Bacillus Calmette-Guérin 
(BCG)-vaccinated, HIV-uninfected Peruvian participants were recruited through Socios En Salud (SES), an 
affiliate of Partners in Health from urban and peri-urban settlements around Lima, Peru, as a case-control 
study. Participants included adults with recently diagnosed microbiologically confirmed, culture-positive, 
drug-sensitive pulmonary TB disease (active TB, n = 48), and clinically asymptomatic household contacts of TB 
patients assessed within two-weeks of diagnosing the index case. Household contacts were evaluated for signs of 
TB disease at the time of enrolment, and were excluded if clinical symptoms of TB were present. Healthy house-
hold contacts were assessed for M.tb infection using QuantiFERON TB-Gold In-Tube (QFT) assays. Participants 
with QFT IFNγ responses > = 0.35 international units (IU)/mL were considered latently M.tb infected 
(QFT-positive, n = 49) and uninfected if QFT IFNγ < 0.35 IU/mL (QFT-negative, n = 47). Household contacts 
were evaluated for signs of TB disease at the time of enrolment, and were excluded when clinical symptoms of 
TB were present. The Institutional Review Board of the Harvard Faculty of Medicine and Partners Healthcare 
(protocol number IRB16-1173), and the Institutional Committee of Ethics in Research of the Peruvian Institutes 
of Health approved the study protocol. All adult study participants and parents and/or legal guardians of minors 
provided informed consent, while minors provided assent. All research was performed in accordance with rel-
evant guidelines/regulations. Peripheral blood mononuclear cells (PBMC) were isolated from 50 mL of venous 
blood using ficoll and cryopreserved at 5 ×106 cells/cryovial, then shipped to the Brigham and Women’s Hospital 
for storage. RNA was extracted from 106 cells PBMCs using the RNeasy extraction kit (Qiagen).
RePORT-Brazil cohort (Diagnostic validation and treatment response). Regional Prospective 
Observational Research for Tuberculosis (RePORT)-Brazil is an ongoing prospective cohort study at five par-
ticipating centers in Brazil: three in Rio de Janeiro (Instituto Nacional de Infectologia (INI), Clinica de Saude 
Rinaldo Delmare (Rochina), Secretaria de Saude de Duque de Caxias (Caxias), one in Salvador (Instituto 
Brasileiro para Investigação da Tuberculose), and one in Manaus (Fundação Medicina Tropical Dr. Heitor Vieira 
Dourado). RePORT-Brazil enrols participants ≥18 years-old who initiate treatment for culture-confirmed pul-
monary TB, and their close contacts. Details of the protocol have been published previously44–46. All participants 
provided written, informed consent and the protocol was approved by the Ethics Committee of the Maternidade 
Climério de Oliveira, Salvador, Brazil. All research was performed in accordance with relevant guidelines/reg-
ulations. Blood was collected in PAXgene tubes at diagnosis in TB cases (active TB, n = 51) and at enrolment in 
contacts (n = 99). Contacts with QFT IFNγ responses > = 0.35 IU/mL were considered latently M.tb infected 
(QFT-positive, n = 22) and uninfected if QFT IFNγ < 0.35 IU/mL (QFT-negative, n = 77).
Capillary blood cohort. Twenty adults (18 years or older) with recently diagnosed, microbiologically con-
firmed pulmonary TB, who were positive for either sputum MGIT or solid culture, Xpert MTB/RIF, Xpert MTB/
RIF Ultra, or smear microscopy within the preceding two weeks and had received no more than two weeks of 
tuberculosis treatment were consecutively recruited from ongoing TB diagnostic and treatment studies at the 
South African Tuberculosis Vaccine Initiative (SATVI) field site. Twenty-nine healthy adults living in commu-
nities from the Cape Winelands region were also enrolled. Individuals with anaemia (haemoglobin less than 
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8.0 g/dl) or any other acute or chronic disease were excluded from both groups but no screening for HIV was 
performed. For each participant, 2.5 mL of venous blood was collected into PAXgene RNA tubes (Qiagen) while 
20 μL, 50 μL or 100 μL capillary blood was collected by fingerprick sequentially using 20 μL or 50 μL Minivettes 
(Sarstedt) without anti-coagulant and immediately transferred into 0.5 mL microtubes (Sarstedt) containing 
PAXgene fluid at an equivalent ratio to the manufacturer’s recommendations, i.e. 1 μL blood: 2.76 μL PAXgene 
fluid. Samples were mixed by inversion (venous PAXgene tubes) or by flicking (capillary blood microtubes), incu-
bated at room temperature for two hours, and stored at −40 °C. Participants provided written informed consent 
and the protocol was approved by the Human Research Ethics committee of the Faculty of Health Sciences at the 
University of Cape Town (HREC 812/2017). All research was performed in accordance with relevant guidelines/
regulations.
Catalysis treatment response cohort, “Catalysis” (TB treatment response in HIV-uninfected 
patients). In total, 131 HIV-uninfected adults with newly diagnosed pulmonary TB, as confirmed by sputum 
culture, were recruited at primary healthcare clinics in Cape Town; 101 completed the study. Disease pathology 
was quantified by positron emission tomography and computerized tomography (PET-CT) imaging using 18F 
FDG at baseline, week 4 and week 24. Total glycolytic activity index (TGAI) is a product of lesion volume and 
FDG uptake intensity and represents the total inflammatory burden, as previously provided18,19. PAXgene tubes 
were collected prior to the start of treatment and at one, four, and 24 weeks after treatment initiation. Of the 101 
sample sets sequenced for a transcriptomics analysis19, 84 patients met or exceeded the WHO definition for cure 
after the standard six-month treatment (“cures”, had proven and then maintained sputum culture negativity by 
month 6). Amongst these, 70 had RNA available for qRT-PCR analysis. Eight patients did not achieve bacterio-
logical cure (classified as “treatment failures”, if the month 6 culture was still positive) and 7 had available RNA. 
None of the treatment failures achieved culture negativity at any time point during treatment and 7 had RNA for 
qRT-PCR analysis). The remaining 10 patients were probable cures (only final culture was negative) or unevalu-
able (treatment response ambiguous) and were not included in any analyses. Twenty-nine healthy controls were 
also enrolled from the same communities and 21 had RNA available for qRT-PCR analysis. All participants pro-
vided written, informed consent and the protocol was approved by the Stellenbosch University Human Research 
Ethics Committee (N10/01/013). All research was performed in accordance with relevant guidelines/regulations.
IMPRESS trial cohort (Recurrent TB treatment response in HIV-infected patients). This study 
was an open-label, randomized controlled trial, “Improving Retreatment Success” (IMPRESS, clinicaltrials.gov, 
NTC02114684; SANCTR DOH-27-0414-4576), performed in Durban, KwaZulu-Natal20. IMPRESS was designed 
to determine if a moxifloxacin-containing 24-week regimen, in which moxifloxacin was substituted for etham-
butol, would improve TB retreatment outcomes relative to the standard TB treatment regimen. The trial enrolled 
adults with a previous history of TB disease who received a new diagnosis of drug-sensitive TB by positive Xpert 
MTB/RIF (Cepheid) or sputum smear microscopy, or both. Sputum samples were collected for culture testing 
every 2 weeks during the intensive phase of treatment and monthly thereafter until successful treatment com-
pletion. Whole blood was collected in PAXgene tubes at baseline, 7 days and 2, 6, 8 and 14 months after start of 
TB treatment. Sixty-three HIV-infected patients had RNA available and were included in the analyses (44 early 
converters, with sputum culture conversion before month 2; and 19 late converters, who converted after month 2). 
The IMPRESS protocol was reviewed and approved by the University of KwaZulu-Natal Biomedical Research 
Ethics Committee (BREC No. BFC029/13). The IMPRESS trial was also approved by the Medicines Control 
Council of South Africa (MCC Ref:20130510). All research was performed in accordance with relevant guide-
lines/regulations and all participants provided written, informed consent.
RNA extraction. RNA was manually extracted from collected PAXgene Blood RNA tubes (Qiagen) with 
the PAXgene blood RNA kit (Qiagen) according to the manufacturer’s instructions or on an automated Tecan 
Freedom EVO 150 robotic platform with the Promega Maxwell SimplyRNA kit, using a modified protocol in 
a biosafety level 2 laboratory. Manually extracted RNA was stored at −80 °C, and later used for transcriptomic 
analysis. For RNA extracted by robotic platform an aliquot was immediately used for cDNA synthesis. For the 
Peruvian cohort, RNA samples were extracted from 106 PBMCs using the RNeasy kit (Qiagen) according to 
manufacturers’ instructions, and blinded, frozen aliquots of RNA were shipped to the University of Cape Town.
For the venous versus capillary blood comparison, RNA was isolated with the PAXgene blood RNA kit 
(Qiagen) according to the manufacturer’s instructions with the following modifications: capillary blood sam-
ples were washed in 400 μL water (instead of 4 ml) and homogenised by pipetting to avoid loss of the small 
pellet; venous and capillary samples were eluted in 80 μL and 40 μL of PAXgene blood RNA kit elution buffer, 
respectively.
Gene expression. cDNA synthesis and all PCR work was performed in a in a biosafety level 2 laboratory. 
cDNA was synthesized from extracted RNA using SuperScript II reverse transcriptase and pre-amplified using a 
pool of specific TaqMan primer-probe sets for microfluidic qRT-PCR. Gene expression of individual transcripts 
was then quantified by microfluidic qRT-PCR using either 96.96 or 192.24 Gene Expression chips on a BioMark 
HD (Fluidigm). An internal positive control sample was run on every chip to monitor inter-chip gene expression 
consistency.
Discovery of a parsimonious prognostic signature of TB disease risk. We sought to develop a 
PCR-based signature comprising a small ensemble of transcript pairs that each represent the ratio between one 
upregulated and one downregulated transcript in progressors, relative to controls, as described previously8. This 
pair-ratio ensemble format presents two advantages. Firstly, the up-down pairing provides a “self-standardisation” 
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function that eliminates the need for housekeeper transcript-based standardisation (normalisation) of RT-PCR 
cycle threshold values. Secondly, the ensemble of pairs provides robustness to the signature since a signature score 
can be calculated even if expression data for one transcript (and its pairs) is not available, due to a failed PCR 
reaction, for example.
Discovery of RISK6 signature of TB disease risk (Supplementary Figure 1a) was performed using all ACS 
cohort progressor/non-progressor samples collected within 360 days of TB disease diagnosis6. We first identi-
fied exon junctions that were differentially expressed in RNA-sequencing data from all progressors and matched 
non-progressors (published in6 and available on GEO: accession number GSE79362). We applied the random 
subsets approach, which randomly selects a partition of half the samples with a quarter of the features, to train 
support vector machines of all possible pairs of junctions using the Pair-Ratio approach. The Pair-Ratio approach 
pairs transcripts that are regulated in opposite directions in progressors and non-progressors. We identified tran-
script pairs that differentiated progressors and non-progressors with the highest sensitivity and specificity on the 
remaining partition of samples not used for fitting. This was repeated until pairs that comprised 84 unique exon 
junctions were identified, such that these could be conveniently assayed, along with 12 housekeeper (reference) 
transcripts, by microfluidic PCR in a 96-reaction format (Supplementary Figure 2).
Training RISK6, a prognostic PCR signature of TB disease risk. Taqman FAM-TAM primer-probe 
assays for each of the 84 exon junctions were used to measure expression of all transcripts by microfluidic 
qRT-PCR using samples from the entire ACS cohort. Delta Ct values were computed for each exon junction 
relative to the geometric mean of the 12 reference transcripts. To train the best parsimonious signature, we eval-
uated fit of pair-ratio ensembles consisting of either 10, 8, 6, 4 or 2 transcript pairs and evaluated their ability to 
differentiate between progressors and non-progressors. An appreciable drop in area under the receiver operating 
characteristic curve (ROC-AUC) was observed for the 2-transcript and 4-transcript ensembles, compared to the 
6-, 8- and 10-transcript pair ratio ensembles (Supplementary Figure 2). As there was no significant difference 
in performance between the 6-, 8- and 10-transcript models, we selected the 6-primer model, which we termed 
RISK6, based on performance and smallest functional ensemble size.
Statistical analysis. All assays were performed on 96.96 or 192.24 Fluidigm gene expression chip format 
in duplicate. Each chip included an internal positive control and negative (no template) control. The following 
parameters were applied for extracting Ct values: Linear (Derivative) baseline correction, Quality Threshold of 
0.65 and Auto (Global) for Ct Threshold Method using Fluidigm software version 3.1.3. Only replicate primer/
probe assays with a ≥80% pass rate across all samples within each gene expression chip, and samples with a ≥ 80% 
replicate assay pass rate within each gene expression chip were retained for downstream analysis. To ensure high 
reproducibility between gene expression chips the RISK6 score obtained for the internal positive control sample 
run on each chip had to fall within a target range established on 11 historical gene expression chips, as 2 standard 
deviations of the mean RISK6 score. Intra-chip correlations between RISK6 assay Ct values of replicates for the 
internal positive control sample had to exceed >0.90. RISK6 scores were computed for each replicate and the final 
score for a sample was considered as the average.
The RISK6 signature score is calculated as follows (R script available on Bitbucket: https://bitbucket.org/satvi/
risk6):
 1. Measure the cycle thresholds (Cts) for the 6 primer-probe assays listed in Supplementary Table 1, by 
qRT-PCR.
 2. For each of the 9 transcript pairs, compute the difference in raw Ct, which produces the log-transformed 
ratio of expression.
 3. Compare the measured ratio to ratios in a look-up table for the given pair of transcripts.
 4. Assign a corresponding score in the look-up table to the ratio. If the measured ratio is larger than all ratios 
in the relevant column of the look-up table, then assign a score of 1 to the ratio.
 5. Compute the average over the scores generated from the set of pairs. If any assays failed on the sample, 
compute the average score over all ratios not including the failed assays. The resulting average is the final 
score for that sample.
There is considerable interest in the biosignature field to apply such signatures to publicly available microar-
ray or RNA-sequencing data11,47. Microarray datasets were obtained programmatically from Gene Expression 
Omnibus and processed using the MetaIntegrator R package, as previously described47. RISK6geo scores were 
computed from the gene-level summarized intensities. RISK6 scores can be computed from log2-transformed 
microarray or RNA-sequencing data using the formula:
=
−
RISK6geo score geometric mean(GBP2, FCGR1B, SERPING1)
geometric mean(TUBGCP6, TRMT2A, SDR39U1)
where normalized log2-transformed mean fluorescence intensity or normalized read count values of GBP2, 
FCGR1B, SERPING1, TUBGCP6, TRMT2A and SDR39U1 are used.
RISK6 scores can also be computed using this method from qRT-PCR data using the formula:
=
−
RISK6geo score geometric mean(TUBGCP6, TRMT2A, SDR39U1)
geometric mean(GBP2, FCGR1B, SERPING1)
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where raw Ct values of GBP2, FCGR1B, SERPING1, TUBGCP6, TRMT2A and SDR39U1 are used. Comparative 
performance characteristics of the RISK6 and RISK6geo signatures for the different cohorts in this study are 
shown in Supplementary Table 2.
qRT-PCR gene expression data was quality controlled using scripts generated in R and signature scores were 
calculated. All RISK6 scores, with the exception of those in the discovery cohort, were generated by blinded 
laboratory personnel. Only once RISK6 score results were locked down and, where appropriate, shared among 
collaborators, were group allocations unblinded for performance analyses. ROC AUCs were generated and com-
pared using the pROC48 and verification49 packages in R. Statistical analyses were done using Mann Whitney 
U for differences between two groups, Wilcoxon ranked sum and Kruskal-Wallis tests for differences between 
three groups in GraphPad Prism v8. To generate spline plots that show temporal changes in transcript expression 
between adolescent progressors and non-progressors, we computed log2 fold change values between progres-
sor and non-progressors transcript abundance (measured by RNA-sequencing) as previously described41, and 
modeled these as a nonlinear function of TimeToDiagnosis for the entire adolescent progressor/non-progressor 
cohort using the smooth.spline function in R with three degrees of freedom. Ninety-nine percent confidence 
intervals for the temporal trends were computed by performing 2000 iterations of spline fitting after bootstrap 
resampling from the full dataset. The median difference and 95% CIs in expression of RISK6 signature genes was 
computed from 1000 bootstrapped median Ct values between HIV+ and HIV-individuals. Genes with 95% CI 
bounds above zero were considered significant.
Data availability
The RISK6 scores and associated clinical data for all cohorts are in Supplementary Tables 5–13.
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